MetaCap

Liquidia (LQDA) vs Travere Therapeutics (TVTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Liquidia (LQDA) has outperformed Travere Therapeutics (TVTX) over the past year, gaining 87.0% versus a gain of 35.5%. Over five years, LQDA leads with a +1224.3% price change compared with +61.9% for TVTX. Liquidia is the larger company by market cap ($4.90 billion vs $4.51 billion), about 1.1 times the size.

On valuation, Travere Therapeutics trades at a lower forward P/E (8.7x vs 15.1x for Liquidia). Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -43.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LQDA+86.98%TVTX+35.49%
+224%+95%-35%
Nov 21, 20251 yearNov 20, 2026
LQDA+1177.70%TVTX+60.57%
+2123%+968%-187%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LQDA versus TVTX key metrics
MetricLQDATVTX
Share price$54.43$47.00
Market cap$4.90B$4.51B
1-day change-3.88%-2.69%
YTD return+57.81%+23.00%
1-year return+86.98%+35.49%
5-year return+1224.33%+61.90%
Forward P/E15.128.68
EPS (TTM)$-1.05$-1.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$158.32M$490.73M
Revenue growth (YoY)+1031.18%+110.45%
Net income (latest FY)$-68.92M$-25.55M
Gross margin—97.89%
Operating margin-32.45%-12.80%
Net margin-43.53%-5.21%
52-week high$93.61$68.73
52-week low$22.31$22.59
Distance from 52-week high-41.85%-31.62%
Analyst consensusbuystrong_buy
Avg. price target upside+21.50%+56.23%
Average volume3.52M1.81M
Shares outstanding90.11M95.99M
Employees216497
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LQDA has outperformed TVTX by 51.5 percentage points over the past year.
  • Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -43.5 cents for Liquidia.
  • Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs +110.45%).

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

About Travere Therapeutics

TVTX stock →

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees

LQDA vs TVTX FAQ

Which is bigger, Liquidia or Travere Therapeutics?

Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.51B for Travere Therapeutics (TVTX).

Which stock has performed better over the past year, LQDA or TVTX?

LQDA returned +86.98% over the past 12 months, compared with +35.49% for TVTX (price return, excluding dividends). Past performance does not predict future results.

Are Liquidia and Travere Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons